Identification of pivotal cellular factors involved in HPV-induced dysplastic and neoplastic cervical pathologies

Journal of Cellular Physiology

Volumn 229, Issue 4, 2014, Pages 463-470

  Mattarocci, Stefano ^a   Abbruzzese, Claudia ^b   Mileo, Anna M ^b   Carosi, Mariantonia ^b   Pescarmona, Edoardo ^b   Vico, Carmen ^b   Federico, Antonio ^b   Vizza, Enrico ^b   Corrado, Giacomo ^b   Arisi, Ivan ^c   Felsani, Armando ^d   Paggi, Marco G ^b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c EUROPEAN BRAIN RESEARCH INSTITUTE   (Italy)

^d CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CTNNB1 PROTEIN; FORMALDEHYDE; GSN PROTEIN; MEMBRANE PROTEIN; MESSENGER RNA; PARAFFIN; PFKM PROTEIN; PROTEIN CDC25A; TOP2A PROTEIN; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

ARTICLE; CANCER GENETICS; CANCER PROGNOSIS; CONTROLLED STUDY; CYTOLOGY; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; UPREGULATION; UTERINE CERVIX CARCINOMA; UTERINE CERVIX DYSPLASIA; WART VIRUS;

EID: 84890458223     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24465     Document Type: Article

References (38)

1. Abbruzzese C, Mattarocci S, Pizzuti L, Mileo AM, Visca P, Antoniani B, Alessandrini G, Facciolo F, Amato R, D'Antona L, Rinaldi M, Felsani A, Perrotti N, Paggi MG. 2012. Determination of SGK1 mRNA in non-small cell lung cancer samples underlines high expression in squamous cell carcinomas. J Exp Clin Cancer Res 31:4.
2. Bellacchio E, Paggi MG. 2013. Understanding the targeting of the RB family proteins by viral oncoproteins to defeat their oncogenic machinery. J Cell Physiol 228:285-291.
3. Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate-A practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol 57:289-300.
4. Branca M, Ciotti M, Giorgi C, Santini D, Di Bonito L, Costa S, Benedetto A, Bonifacio D, Di Bonito P, Paba P, Accardi L, Syrjanen S, Favalli C, Syrjanen K. 2008. Predicting high-risk human papillomavirus infection, progression of cervical intraepithelial neoplasia, and prognosis of cervical cancer with a panel of 13 biomarkers tested in multivariate modeling. Int J Gynecol Pathol 27:265-273.
5. Brown CA, Bogers J, Sahebali S, Depuydt CE, De PF, Malinowski DP. 2012. Role of protein biomarkers in the detection of high-grade disease in cervical cancer screening programs. J Oncol 2012:289315.
6. Chellappan S, Kraus VB, Kroger B, Munger K, Howley PM, Phelps WC, Nevins JR. 1992. Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proc Natl Acad Sci USA 89:4549-4553.
7. Cheng Y, Zhou Y, Jiang W, Yang X, Zhu J, Feng D, Wei Y, Li M, Yao F, Hu W, Xiao W, Ling B. 2012. Significance of E-cadherin, beta-catenin, and vimentin expression as postoperative prognosis indicators in cervical squamous cell carcinoma. Hum Pathol 43:1213-1220.
8. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M. 2012. Global burden of cancers attributable to infections in 2008: A review and synthetic analysis. Lancet Oncol 13:607-615.
9. Dvinge H, Bertone P. 2009. HTqPCR: High-throughput analysis and visualization of quantitative real-time PCR data in R. Bioinformatics 25:3325-3326.
10. Ewen ME. 1994. The cell cycle and the retinoblastoma protein family [review]. Cancer Metastasis Rev 13:45-66.
11. Fehrmann F, Laimins LA. 2003. Human papillomaviruses: Targeting differentiating epithelial cells for malignant transformation. Oncogene 22:5201-5207.
12. Felsani A, Mileo AM, Paggi MG. 2006. Retinoblastoma family proteins as key targets of the small DNA virus oncoproteins. Oncogene 25:5277-5285.
13. Gao G, Peng M, Zhu L, Wei Y, Wu X. 2009. Human papillomavirus 16 variant E7 gene induces transformation of NIH 3T3 cells via up-regulation of cdc25A and cyclin A. Int J Gynecol Cancer 19:494-499.
14. Guo M, Baruch AC, Silva EG, Jan YJ, Lin E, Sneige N, Deavers MT. 2011. Efficacy of p16 and ProExC immunostaining in the detection of high-grade cervical intraepithelial neoplasia and cervical carcinoma. Am J Clin Pathol 135:212-220.
15. Hateboer G, Kerkhoven RM, Shvarts A, Bernards R, Beijersbergen RL. 1996. Degradation of E2F by the ubiquitin-proteasome pathway: Regulation by retinoblastoma family proteins and adenovirus transforming proteins. Genes Dev 10:2960-2970.
16. Helt AM, Galloway DA. 2003. Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins. Carcinogenesis 24:159-169.
17. Mattarocci S, Abbruzzese C, Mileo AM, Visca P, Antoniani B, Alessandrini G, Facciolo F, Felsani A, Radulescu RT, Paggi MG. 2009. Intracellular presence of insulin and its phosphorylated receptor in non-small cell lung cancer. J Cell Physiol 221:766-770.
18. Mazurek S, Zwerschke W, Jansen-Durr P, Eigenbrodt E. 2001. Effects of the human papilloma virus HPV-16 E7 oncoprotein on glycolysis and glutaminolysis: Role of pyruvate kinase type M2 and the glycolytic-enzyme complex. Biochem J 356:247-256.
19. McLaughlin-Drubin ME, Munger K. 2009. The human papillomavirus E7 oncoprotein. Virology 384:335-344.
20. Mileo AM, Piombino E, Severino A, Tritarelli A, Paggi MG, Lombardi D. 2006. Multiple interference of the human papillomavirus-16 E7 oncoprotein with the functional role of the metastasis suppressor Nm23-H1 protein. J Bioenerg Biomembr 38:215-225.
21. Mileo AM, Abbruzzese C, Mattarocci S, Bellacchio E, Pisano P, Federico A, Maresca V, Picardo M, Giorgi A, Maras B, Schinina ME, Paggi MG. 2009. Human papillomavirus-16 E7 interacts with glutathione S-transferase P1 and enhances its role in cell survival. PLoS ONE 4:e7254.
22. Mileo AM, Abbruzzese C, Vico C, Bellacchio E, Matarrese P, Ascione B, Federico A, Della BS, Mattarocci S, Malorni W, Paggi MG. 2013. The Human papillomavirus-16 E7 oncoprotein exerts anti-apoptotic effects via its physical interaction with the actin-binding protein gelsolin. Carcinogenesis doi: 10.1093/carcin/bgt192
23. Morris JD, Crook T, Bandara LR, Davies R, LaThangue NB, Vousden KH. 1993. Human papillomavirus type 16 E7 regulates E2F and contributes to mitogenic signalling. Oncogene 8:893-898.
24. Mulligan G, Jacks T. 1998. The retinoblastoma gene family: Cousins with overlapping interests. Trends Genet 14:223-229.
25. Munger K, Basile JR, Duensing S, Eichten A, Gonzalez SL, Grace M, Zacny VL. 2001. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 20:7888-7898.
26. Munger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, Grace M, Huh K. 2004. Mechanisms of human papillomavirus-induced oncogenesis. J Virol 78:11451-11460.
27. Nguyen DX, Westbrook TF, McCance DJ. 2002. Human papillomavirus type 16 E7 maintains elevated levels of the cdc25A tyrosine phosphatase during deregulation of cell cycle arrest. J Virol 76:619-632.
28. Paggi MG, Giordano A. 2001. Who is the boss in the retinoblastoma family? The point of view of Rb2/p130, the little brother. Cancer Res 61:4651-4654.
29. Paggi MG, Baldi A, Bonetto F, Giordano A. 1996. Retinoblastoma protein family in cell cycle and cancer: A review. J CellBiochem 62:418-430.
30. Saeed AI, Bhagabati NK, Braisted JC, Liang W, Sharov V, Howe EA, Li J, Thiagarajan M, White JA, Quackenbush J. 2006. TM4 microarray software suite. Methods Enzymol 411:134-193.
31. Severino A, Abbruzzese C, Manente L, Avivar Valderas A, Mattarocci S, Federico A, Starace G, Chersi A, Mileo AM, Paggi MG. 2007. Human papillomavirus-16 E7 interacts with Siva-1 and modulates apoptosis in HaCaT human immortalized keratinocytes. J Cell Physiol 212:118-125.
32. Siegel R, Naishadham D, Jemal A. 2013. Cancer statistics, 2013. CA Cancer J Clin 63:11-30.
33. Smyth GK, Michaud J, Scott HS. 2005. Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics 21:2067-2075.
34. Tamada M, Suematsu M, Saya H. 2012. Pyruvate kinase m2: Multiple faces for conferring benefits on cancer cells. Clin Cancer Res 18:5554-5561.
35. Weinberg RA. 1995. The retinoblastoma protein and cell cycle control. Cell 81:323-330.
36. Whiteside MA, Siegel EM, Unger ER. 2008. Human papillomavirus and molecular considerations for cancer risk. Cancer 113:2981-2994.
37. zur Hausen H. 2009. The search for infectious causes of human cancers: Where and why (Nobel lecture). Angew Chem Int Ed Engl 48:5798-5808.
38. Zwerschke W, Mazurek S, Massimi P, Banks L, Eigenbrodt E, Jansen-Durr P. 1999. Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein. Proc Natl Acad Sci USA 96:1291-1296.